Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.47M | 3.07M | 3.27M | 3.60M | 2.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.88M | 8.26M | 7.12M | 7.48M | 6.27M |
| Operating Income | -6.88M | -8.26M | -7.12M | -7.48M | -6.27M |
| Income Before Tax | -6.37M | -8.74M | -6.76M | -7.53M | -5.99M |
| Income Tax Expenses | -600.00 | 5.60K | 2.80K | 1.80K | -- |
| Earnings from Continuing Operations | -6.37M | -8.75M | -6.77M | -7.53M | -5.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.00K | 6.80K | 4.70K | 23.40K | 48.00K |
| Net Income | -6.36M | -8.74M | -6.76M | -7.51M | -5.94M |
| EBIT | -6.88M | -8.26M | -7.12M | -7.48M | -6.27M |
| EBITDA | -6.84M | -8.23M | -7.10M | -14.83M | -6.25M |
| EPS Basic | -0.19 | -0.26 | -0.21 | -0.43 | -0.17 |
| Normalized Basic EPS | -0.11 | -0.15 | -0.12 | -0.13 | -0.10 |
| EPS Diluted | -0.19 | -0.26 | -0.21 | -0.44 | -0.17 |
| Normalized Diluted EPS | -0.11 | -0.15 | -0.12 | -0.13 | -0.10 |
| Average Basic Shares Outstanding | 36.92M | 35.93M | 35.69M | 35.64M | 35.62M |
| Average Diluted Shares Outstanding | 36.92M | 35.93M | 35.69M | 35.64M | 35.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |